Analyst ahead of Genmab report: Focus will be on Darzalex prognosis
Genmab’s 2022 guidance will take center stage when the company presents its full-year financial report on Wednesday.
by marketwire, translated by daniel pedersen
Some of the excitement has been taken out of Genmab’s full-year financial report, which will be publicized on Wednesday. The company’s partner Johnson & Johnson has already published figures for Genmab’s biggest source of revenue, cancer drug Darzalex.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Janssen submits Genmab-developed drug for EMA approval
For subscribers
Genmab: Darzalex sales in line with expectations
For subscribers
Anthony Mancini will help Genmab take its next steps
For subscribers
